In addition, an integrated database for exosome-based biomarker discovery (ExoBCD) evidenced IGF1R and FRS2 as the most promising prognostic circulating biomarkers for clinical use in breast cancer [98]. The gene discussed is IGF1R; the disease is breast carcinoma.